Premier to Offer Members Access to Meridian's Illumigene MDx Tests | GenomeWeb

NEW YORK (GenomeWeb) – Meridian Bioscience today announced an agreement with healthcare alliance Premier to offer Meridian's illumigene molecular tests.

Premier serves more than 3,000 hospitals and 110,000 other healthcare sites. Under the agreement, Premier facilities will offer Meridian's tests for C. difficile, Group A and B Streptococcus, Bordetella pertussis, and Mycoplasma pneumoniae on the illumigene platform, which uses loop-mediated isothermal DNA amplification technology to provide results in less than one hour.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.